Fusion Pharmaceuticals
Based in Hamilton, ON & Boston, MA, Fusion is developing next-generation radiopharmaceuticals for precision oncology.
Based in Hamilton, ON & Boston, MA, Fusion is developing next-generation radiopharmaceuticals for precision oncology.
Fusion Pharmaceuticals is a clinical-stage oncology company headquartered in Hamilton, ON, Canada, with offices in Boston, MA. The company specializes in developing next-generation radiopharmaceuticals as precision medicines, utilizing a proprietary Fast-Clear linker technology to connect alpha particle emitting isotopes to antibodies and targeting molecules for selective delivery of alpha emitting payloads to tumors. Their lead program, FPI-1434, is currently undergoing a Phase 1 clinical trial. Fusion recently received a substantial $60.00M Post-IPO Equity investment on 13 February 2023, with notable participation from investors including Invus, Perceptive Advisors, Woodline Partners, Federated Kaufmann Fund, and Avidity Partners. The company's focus on innovative radiopharmaceuticals positions it at the forefront of the evolving landscape of precision oncology, making it an attractive prospect for strategic investment within the biopharma, biotechnology, and pharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $60.00M | 5 |
|
13 Feb 2023 |
| Venture Round | $26.00M | 1 | Canada Pension Plan Investment Board | 13 Jan 2020 |
| Series B | $105.00M | 4 |
|
01 Apr 2019 |
| Series A | $21.00M | - | 25 Sep 2017 | |
| Series A | $25.00M | - | 23 Feb 2017 |
We care about your data, and we'd love to use cookies make your experience better.
